Data report · 2026
The State of Peptide Clinics 2026
What does the peptide, hormone and longevity clinic market actually look like in 2026? We analysed every clinic listed and reviewed in the Peptide Clinic Finder directory — 250 clinics across the United States, United Kingdom, Canada and Ireland — to see which treatments they offer, where they cluster, and what that says about demand. The data and charts below are free to cite with attribution to Peptide Clinic Finder.
250
listed clinics
4
countries
32
cities
71%
flagged verified at publication
Note on the 71% figure: it is the share of this 250-clinic sample that carried the directory's internal “verified” classification when the study was published in July 2026, based on each clinic's own published information. It is not a count of independently verified clinics, and it is not the current PCF Verified badge, which requires a confirmed entry in an official public register. The published figures on this page are kept unchanged for citation. What each label means.
Clinics by country
| Country | Clinics | Cities covered |
|---|---|---|
| United States | 119 | 14 |
| United Kingdom | 112 | 15 |
| Canada | 12 | 2 |
| Ireland | 7 | 1 |
Where clinics cluster: top 10 cities
| City | Clinics |
|---|---|
| London, UK | 27 |
| Miami, US | 19 |
| Los Angeles, US | 15 |
| New York, US | 14 |
| San Diego, US | 9 |
| Chicago, US | 8 |
| Birmingham, UK | 7 |
| Phoenix, US | 7 |
| Bristol, UK | 7 |
| Glasgow, UK | 7 |
What clinics actually offer (share of all clinics)
Each clinic typically offers several treatments, so these shares overlap. They show how common each treatment is across the directory.
| Treatment | Clinics offering | Share |
|---|---|---|
| Semaglutide (GLP-1) | 91 | 36% |
| Tirzepatide (GLP-1/GIP) | 80 | 32% |
| BPC-157 (recovery peptide) | 69 | 28% |
| Ipamorelin (GH secretagogue) | 63 | 25% |
| CJC-1295 (GH secretagogue) | 60 | 24% |
| Hormone optimisation | 60 | 24% |
| Testosterone / TRT | 54 | 22% |
Key findings
GLP-1 weight-loss is the front door
Semaglutide (36% of clinics) and tirzepatide (32%) are the most widely offered treatments by some distance. The peptide-clinic category is, in practice, being pulled along by the GLP-1 weight-loss boom — it's the entry point that brings most patients through the door.
Recovery peptides are mainstream, not fringe
BPC-157 is offered by roughly 28% of clinics — nearly as common as tirzepatide — despite being an unapproved, prescription-route compound. Demand for recovery and regenerative peptides is no longer niche.
The US leads on volume, the UK on city spread
United States has the most clinics (119), but United Kingdom is close behind (112) and is spread across more cities (15 vs 14) — a more decentralised market rather than a few big hubs.
Supply clusters in a handful of cities
London, Miami, Los Angeles and New York alone account for a large share of listings. Patients outside these hubs increasingly rely on telehealth or travel — a real access gap.
Cite this report
Journalists, researchers and writers are welcome to reference these figures with attribution to Peptide Clinic Finder and a link to this page (peptideclinicfinder.com/state-of-peptide-clinics-2026). For a specific cut of the data or a comment, use the contact page.
Methodology
Figures are based on the 250 clinics listed and reviewed in the Peptide Clinic Finder directory as of July 2026, across the United States, United Kingdom, Canada and Ireland. Treatment figures reflect the services each clinic lists publicly or via our review process; because clinics offer multiple treatments, treatment shares overlap and do not sum to 100%. The internal “verified” classification behind the 71% figure reflects the directory review classification as it stood at publication in July 2026; it does not correspond to the current PCF Verified badge, which requires confirmed official public-register evidence. This is a directory snapshot, not a census of every clinic in each market, and it will grow as coverage expands. Peptide Clinic Finder is an informational directory and does not diagnose, prescribe, or recommend treatment.
Every figure on this page is fixed to the July 2026 sample so that citations stay stable and reproducible. The directory has continued to change since then, so today's total will differ from the 250 clinics analysed here — the current count is shown on the clinic directory. We will publish a new dated edition rather than restate these numbers.